| Cover - shares | 3 Months Ended | |
| Mar. 31, 2022 | May 13, 2022 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Mar. 31, 2022 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2022 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 000-54785 | |
| Entity Registrant Name | GLUCOTRACK, INC. | |
| Entity Central Index Key | 0001506983 | |
| Entity Tax Identification Number | 98-0668934 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 8 Ariel Sharon Street | |
| Entity Address, Address Line Two | P.O. Box 6037607 | |
| Entity Address, City or Town | Or Yehuda | |
| Entity Address, Country | IL | |
| Entity Address, Postal Zip Code | 7760049 | |
| City Area Code | 972 (8) | |
| Local Phone Number | 675-7878 | |
| Title of 12(b) Security | Common | |
| Trading Symbol | GCTK | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 15,461,757 |
| Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
| Current Assets | ||
| Cash and cash equivalents | $ 4,789 | $ 6,062 |
| Other current assets | 442 | 43 |
| Total current assets | 5,231 | 6,105 |
| Operating lease right-of-use assets, net | 18 | 40 |
| Property and equipment, net | 60 | 69 |
| Restricted Cash | 50 | 51 |
| TOTAL ASSETS | 5,359 | 6,265 |
| Current Liabilities | ||
| Accounts payable | 590 | 631 |
| Operating lease liabilities, current | 12 | 23 |
| Other current liabilities | 314 | 229 |
| Total Current Liabilities | 916 | 883 |
| Non-current Liabilities | ||
| Loans from stockholders | 206 | 210 |
| Operating lease liabilities, non-current | 6 | 17 |
| Total non-current liabilities | 212 | 227 |
| Total liabilities | 1,128 | 1,110 |
| Stockholders’ Equity | ||
| Common Stock Value | 15 | 15 |
| Additional paid-in capital | 102,763 | 102,612 |
| Accumulated other comprehensive income (loss) | 1 | (6) |
| Receipts on account of shares | 11 | |
| Accumulated deficit | (98,559) | (97,466) |
| Total Stockholders’ equity | 4,231 | 5,155 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 5,359 | $ 6,265 |
| Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
| Statement of Financial Position [Abstract] | ||
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 500,000,000,000 | 500,000,000,000 |
| Common stock, shares issued | 15,452,285 | 15,452,285 |
| Common stock, shares outstanding | 15,452,285 | 15,452,285 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Income Statement [Abstract] | ||
| Research and development expenses | $ 460 | $ 309 |
| Marketing expenses | 23 | |
| General and administrative expenses | 633 | 564 |
| Total operating expenses | 1,093 | 896 |
| Operating loss | 1,093 | 896 |
| Financing expense, net | 8 | |
| Loss for the period | 1,093 | 904 |
| Other comprehensive income: | ||
| Foreign currency translation income | (7) | (22) |
| Comprehensive loss for the period | $ 1,086 | $ 882 |
| Loss per share (Basic and Diluted) | $ (0.07) | $ (0.06) |
| Weighted average number of common stock outstanding used in computing basic and diluted net loss per share | 15,461,757 | 15,444,697 |
| Condensed Consolidated Statements of Changes In Stockholders' Equity(Deficit) - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Receipts on Account of Shares [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total | |
| Beginning balance, value at Dec. 31, 2020 | $ 15 | $ 102,351 | $ 15 | $ (93,399) | $ 8,982 | ||
| Beginning balance, shares at Dec. 31, 2020 | 15,444,697 | ||||||
| Loss for the period of three months | (904) | (904) | |||||
| Other comprehensive income | 22 | 22 | |||||
| Stock-based compensation | 49 | 49 | |||||
| Ending balance, value at Mar. 31, 2021 | $ 15 | 102,400 | 37 | (94,303) | 8,149 | ||
| Ending balance, shares at Mar. 31, 2021 | 15,444,697 | ||||||
| Beginning balance, value at Dec. 31, 2021 | $ 15 | 102,612 | (6) | (97,466) | 5,155 | ||
| Beginning balance, shares at Dec. 31, 2021 | 15,452,285 | ||||||
| Loss for the period of three months | (1,093) | (1,093) | |||||
| Other comprehensive income | 7 | 7 | |||||
| Stock-based compensation | 151 | 151 | |||||
| Issuance of restricted shares as compensation towards directors (*) | [1] | 11 | 11 | ||||
| Ending balance, value at Mar. 31, 2022 | $ 15 | $ 102,763 | $ 11 | $ 1 | $ (98,559) | $ 4,231 | |
| Ending balance, shares at Mar. 31, 2022 | 15,452,285 | ||||||
| [1] | Actual issuance occurred subsequent to the balance sheet date. | ||||||
| Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | ||
| Mar. 31, 2022 | Mar. 31, 2021 | ||
| Cash flows from operating activities: | |||
| Loss for the period | $ (1,093) | $ (904) | |
| Adjustments to reconcile loss for the period to net cash used in operating activities: | |||
| Depreciation | 9 | 12 | |
| Stock-based compensation | 151 | 49 | |
| Issuance of restricted shares as compensation towards directors (*) | [1] | 11 | |
| Linkage difference on principal of loans from stockholders | 2 | 2 | |
| Changes in assets and liabilities: | |||
| Increase in accounts receivable | (5) | ||
| Increase in inventory | (6) | ||
| Increase (Decrease) in other current assets | (400) | 10 | |
| Decrease in accounts payable | (35) | (155) | |
| Increase in other current liabilities | 90 | 64 | |
| Net cash used in operating activities | (1,265) | (933) | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (9) | 1 | |
| Change in cash, cash equivalents, and restricted cash | (1,274) | (932) | |
| Cash, cash equivalents, and restricted cash at beginning of the period | 6,113 | 9,885 | |
| Cash, cash equivalents, and restricted cash at end of the period | $ 4,839 | $ 8,953 | |
| [1] | Actual issuance occurred subsequent to the balance sheet date. | ||
| GENERAL | 3 Months Ended |
| Mar. 31, 2022 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| GENERAL | NOTE 1 – GENERAL A. GlucoTrack Inc (Formerly: Integrity Applications, Inc.) (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. On July 15, 2010, GlucoTrack Acquisition Corp. Ltd. (hereinafter: “Integrity Acquisition”), a wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: “Integrity Israel”), an Israeli corporation that was previously held by the stockholders of the Company. Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company. As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002 The Company and Integrity Israel are referred as the “Group”. On December 8, 2021, the Company announced that its shares of common stock were approved for listing on the Nasdaq Capital Market (“NASDAQ”). Trading on NASDAQ commenced on December 10, 2021 under its existing trading symbol, IGAP. On March 14, 2022, the Company announced that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market (from IGAP to GCTK), to be effective at the commencement of trading on March 14, 2022. In connection with its application to list its shares on Nasdaq Capital Market (“NASDAQ”), as detailed above, on August 13, 2021, the Company effected a reverse split of its Common Stock in a ratio of 1 for 13 (the “Reverse Share Split”). For accounting purposes, all Shares, options and warrants to purchase Common Stock and loss per share amounts have been adjusted to give retroactive effect to this Reverse Share Split for all periods presented in these consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. B. Going concern uncertainty Since its incorporation, the Company did not conduct any material operations other than those carried out by Integrity Israel a medical device company, which focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. The development and commercialization of Integrity Israel’s product is expected to require substantial expenditures. The Company and Integrity Israel have not yet generated significant revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of March 31, 2022, the 98,559 4,789 The Company plans to finance its operations through the sale of equity and/or debt securities (including shelf registration statement on Form S-3 that was declared effective on September 27, 2021 by the Securities and Exchange Commission (SEC) and which allows the Company to register up to $ 100,000 GLUCOTRACK INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (cont.) |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
| Mar. 31, 2022 | |
| Accounting Policies [Abstract] | |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. Basis of presentation Accounting Principles The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Net Loss Per Share Basic loss per share is computed by dividing the loss for the period applicable for holders of our Common Stock by the weighted average number of shares of Common Stock outstanding during the period. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method”, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants. Shares that will be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive. Total weighted average number of 6,452,510 and 6,481,598 outstanding stock options and stock warrants have been excluded from the calculation of the diluted net loss per share for the period of three months ended March 31, 2022 and 2021, respectively, because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was determined to be anti-dilutive. GLUCOTRACK INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) B. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated interim condensed financial statements, the most significant estimates and assumptions relate to the going concern assumptions. C. Reclassified Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s equity or cash flows . GLUCOTRACK INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (cont.) |
| Cash and cash equivalents | 3 Months Ended |
| Mar. 31, 2022 | |
| Cash and Cash Equivalents [Abstract] | |
| Cash and cash equivalents | NOTE 3 – Cash and cash equivalents SCHEDULE OF CASH AND CASH EQUIVALENTS 2022 2021 US dollars March 31, December 31, 2022 2021 US Dollar 4,776 6,028 Other 13 34 Total 4,789 6,062 |
| SUBSEQUENT EVENTS | 3 Months Ended |
| Mar. 31, 2022 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | NOTE 4 – SUBSEQUENT EVENTS The Company has evaluated all subsequent events through the date when these financial statements were issued to determine if these must be reported. The Company determined that there were no reportable subsequent events to disclose in these financial statements. |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
| Mar. 31, 2022 | |
| Accounting Policies [Abstract] | |
| Basis of presentation | A. Basis of presentation Accounting Principles The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Net Loss Per Share Basic loss per share is computed by dividing the loss for the period applicable for holders of our Common Stock by the weighted average number of shares of Common Stock outstanding during the period. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method”, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants. Shares that will be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive. Total weighted average number of 6,452,510 and 6,481,598 outstanding stock options and stock warrants have been excluded from the calculation of the diluted net loss per share for the period of three months ended March 31, 2022 and 2021, respectively, because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was determined to be anti-dilutive. GLUCOTRACK INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) |
| Use of estimates in the preparation of financial statements | B. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated interim condensed financial statements, the most significant estimates and assumptions relate to the going concern assumptions. |
| Reclassified Amounts | C. Reclassified Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s equity or cash flows . |
| Cash and cash equivalents (Tables) | 3 Months Ended |
| Mar. 31, 2022 | |
| Cash and Cash Equivalents [Abstract] | |
| SCHEDULE OF CASH AND CASH EQUIVALENTS | SCHEDULE OF CASH AND CASH EQUIVALENTS 2022 2021 US dollars March 31, December 31, 2022 2021 US Dollar 4,776 6,028 Other 13 34 Total 4,789 6,062 |
| GENERAL (Details Narrative) - USD ($) $ in Thousands | Aug. 13, 2021 | Mar. 31, 2022 | Dec. 31, 2021 |
| Subsidiary, Sale of Stock [Line Items] | |||
| Stockholders' Equity, Reverse Stock Split | 1 for 13 | ||
| Retained Earnings (Accumulated Deficit) | $ 98,559 | $ 97,466 | |
| Cash | 4,789 | ||
| Private Placement [Member] | |||
| Subsidiary, Sale of Stock [Line Items] | |||
| Debt securities | $ 100,000 |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Accounting Policies [Abstract] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 6,452,510 | 6,481,598 |
| SCHEDULE OF CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
| Total | $ 4,789 | $ 6,062 |
| US Dollar [Member] | ||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
| Total | 4,776 | 6,028 |
| Other [Member] | ||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
| Total | $ 13 | $ 34 |
